Approval based on direct-to-Phase 3 program showing more than
three times as many Dupixent patients (60% and 58%) experienced
clinically meaningful itch reduction at 24 weeks compared to
placebo (18% and 20%)
Dupixent also significantly reduced skin lesions and improved
health-related quality of life compared to placebo
In Europe, about 70,000
adults living with prurigo nodularis are most in need of new
treatment options
Dupixent now approved to treat four chronic inflammatory
diseases in the EU
TARRYTOWN, N.Y. and PARIS, Dec. 15,
2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) and Sanofi today announced that the European
Commission (EC) has expanded the marketing authorization for
Dupixent® (dupilumab) in the European Union to treat
adults with moderate-to-severe prurigo nodularis who are candidates
for systemic therapy. Prurigo nodularis is a chronic, debilitating
skin disease with underlying type 2 inflammation and its impact on
quality of life is one of the highest among inflammatory skin
diseases. With this approval, Dupixent is the first and only
targeted medicine specifically indicated to treat prurigo nodularis
in Europe and the U.S.
"For the first time, patients with prurigo nodularis in
Europe have a medicine that can
help relieve the burden of itchy and painful nodules covering their
skin, which can have a devastating impact on their day-to-day
lives, both physically and mentally," said George D. Yancopoulos, M.D., Ph.D., President
and Chief Scientific Officer at Regeneron, and a principal inventor
of Dupixent. "Dupixent is now approved for its second
dermatological disease and fourth disease overall. We remain
committed to further investigating this innovative medicine for
diseases – such as chronic urticarias and chronic obstructive
pulmonary disease – in which type 2 inflammation may play a
role."
"As the first and only targeted medicine approved to treat
people living with prurigo nodularis, Dupixent has the potential to
transform the standard-of-care for people in Europe living with this debilitating skin
disease. In the pivotal trials, patients treated with Dupixent
experienced significant improvements in key hallmarks of the
disease, such as reduction in itch and achieving clearer skin, as
well as broader impacts on their daily lives," Naimish Patel, M.D. Head of Global Development,
Immunology and Inflammation at Sanofi. "This approval of Dupixent
underscores our continued commitment to bringing Dupixent to
patients suffering from chronic skin diseases with underlying type
2 inflammation as quickly as possible."
The EC decision is based on data from two Phase 3 trials, PRIME
and PRIME2, evaluating the efficacy and safety of Dupixent (PRIME
n=75; PRIME2 n=78) in adults with uncontrolled prurigo nodularis
compared to placebo (PRIME n=76; PRIME2 n=82). In these trials, 44%
and 37% of Dupixent patients experienced a clinically meaningful
reduction in itch at 12 weeks, compared to 16% and 22% for placebo,
respectively. The improvement further increased at 24 weeks, with
approximately three times as many Dupixent patients (60% and 58%)
experiencing a clinically meaningful reduction in itch from
baseline, compared to placebo (18% and 20%).
In PRIME and PRIME2, more than twice as many Dupixent patients
(48% and 45%) also achieved clear or almost clear skin at 24 weeks,
compared to placebo (18% and 16%). Dupixent also significantly
improved health-related quality of life, while reducing measures of
skin pain and symptoms of anxiety/depression from baseline at 24
weeks compared to placebo.
The safety results of the trial were generally consistent with
the known safety profile of Dupixent in its approved indications,
with the most common side effects across indications including
injection site reactions, conjunctivitis, conjunctivitis allergic,
arthralgia, oral herpes and eosinophilia. Adverse events more
commonly observed in prurigo nodularis with Dupixent compared to
placebo included conjunctivitis (4% Dupixent and 1% placebo).
About Prurigo Nodularis
Prurigo nodularis is a
chronic, debilitating skin disease with underlying type 2
inflammation and has one of the highest impacts on a patient's
quality of life among inflammatory skin diseases due to the extreme
itch it causes. Those with prurigo nodularis experience intense,
persistent itch with thick skin lesions (called nodules) that can
cover most of the body. The disease is often painful – with
burning, stinging and tingling of the skin – and can negatively
affect mental health, activities of daily living and social
interactions. High-potency topical steroids are commonly prescribed
but are associated with safety risks if used long-term. In
Europe, about 70,000 adults living
with prurigo nodularis are most in need of new treatment
options.
About the Dupixent Prurigo Nodularis Trials
The PRIME
and PRIME2 Phase 3 double-blind, placebo-controlled trials
evaluated the efficacy and safety of Dupixent in 311 adults with
uncontrolled prurigo nodularis. In PRIME and PRIME2, the primary
endpoint evaluated the proportion of patients with clinically
meaningful improvement in itch from baseline (measured by a
≥4-point reduction in Worst-Itch Numeric Rating Scale [WI-NRS] on a
0-10 scale) at 24 and 12 weeks, respectively.
Additional endpoints included the proportion of patients with
clear or almost clear skin of nodules at 24 weeks (measured by a
score of 0 or 1 on the Investigator's Global Assessment PN-Stage
[IGA PN-S] on a 0-4 scale), the proportion of patients who achieved
a clinically meaningful response in both WI-NRS and IGA PN-S,
improvement from baseline in health-related quality of life
(measured by the Dermatology Life Quality Index [DLQI] on a 0-30
scale), improvement from baseline in skin pain (measured by a
Numerical Rating Scale from 0-10), and improvement from baseline in
symptoms of anxiety and depression (measured by the Hospital
Anxiety and Depression Scale [HADS] from 0-42).
About Dupixent
Dupixent is an injection under the skin
(subcutaneous injection) at different injection sites. In the EU
for adults with prurigo nodularis, Dupixent is administered at 300
mg every two weeks, following a loading dose. It is available as
both a pre-filled pen and pre-filled syringe at the 300 mg dose.
Dupixent is intended for use under the guidance of a healthcare
professional and can be given in a clinic or at home by
self-administration after training by a healthcare
professional.
Dupixent, which was invented using Regeneron's proprietary
VelocImmune® technology, is a fully human
monoclonal antibody that inhibits the signaling of the
interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not
an immunosuppressant. The Dupixent development program has shown
significant clinical benefit and a decrease in type 2 inflammation
in Phase 3 trials, establishing that IL-4 and IL-13 are key and
central drivers of the type 2 inflammation that plays a major role
in multiple related and often co-morbid diseases. These diseases
include approved indications for Dupixent, such as atopic
dermatitis, asthma, chronic rhinosinusitis with nasal polyposis
(CRSwNP) and prurigo nodularis, as well as investigational disease
eosinophilic esophagitis (EoE) in the EU.
Dupixent has received regulatory approvals in one or more
countries around the world for use in certain patients with atopic
dermatitis, asthma, CRSwNP, EoE or prurigo nodularis in different
age populations. Dupixent is currently approved for one or more of
these indications in more than 60 countries, including in
Europe, the U.S. and Japan. More than 500,000 patients have been
treated with Dupixent globally.
About Regeneron's VelocImmune
Technology
Regeneron's VelocImmune technology
utilizes a proprietary genetically engineered mouse platform
endowed with a genetically humanized immune system to produce
optimized fully human antibodies. When Regeneron's co-Founder,
President and Chief Scientific Officer George D. Yancopoulos was a graduate student
with his mentor Frederick W. Alt in
1985, they were the first to envision making such a genetically
humanized mouse, and Regeneron has spent decades inventing and
developing VelocImmune and related VelociSuite®
technologies. Dr. Yancopoulos and his team have used VelocImmune
technology to create approximately one in five of all original,
FDA-approved or authorized fully human monoclonal antibodies. This
includes REGEN-COV® (casirivimab and imdevimab),
Dupixent, Libtayo® (cemiplimab-rwlc),
Praluent® (alirocumab), Kevzara® (sarilumab),
Evkeeza® (evinacumab-dgnb) and Inmazeb®
(atoltivimab, maftivimab and odesivimab-ebgn).
Dupilumab Development Program
Dupilumab is being
jointly developed by Regeneron and Sanofi under a global
collaboration agreement. To date, dupilumab has been studied across
more than 60 clinical trials involving more than 10,000 patients
with various chronic diseases driven in part by type 2
inflammation.
In addition to the currently approved indications, Regeneron and
Sanofi are studying dupilumab in a broad range of diseases driven
by type 2 inflammation or other allergic processes in Phase 3
trials, including pediatric EoE, hand and foot atopic dermatitis,
chronic inducible urticaria-cold, chronic spontaneous urticaria,
chronic pruritus of unknown origin, chronic obstructive pulmonary
disease with evidence of type 2 inflammation, chronic
rhinosinusitis without nasal polyposis, allergic fungal
rhinosinusitis, allergic bronchopulmonary aspergillosis and bullous
pemphigoid. These potential uses of dupilumab are currently under
clinical investigation, and the safety and efficacy in these
conditions have not been fully evaluated by any regulatory
authority.
U.S. INDICATIONS
DUPIXENT is a prescription medicine used:
- to treat adults and children 6 months of age and older with
moderate-to-severe eczema (atopic dermatitis or AD) that is not
well controlled with prescription therapies used on the skin
(topical), or who cannot use topical therapies. DUPIXENT can be
used with or without topical corticosteroids. It is not known if
DUPIXENT is safe and effective in children with atopic dermatitis
under 6 months of age.
- with other asthma medicines for the maintenance treatment of
moderate-to-severe eosinophilic or oral steroid dependent asthma in
adults and children 6 years of age and older whose asthma is not
controlled with their current asthma medicines. DUPIXENT helps
prevent severe asthma attacks (exacerbations) and can improve your
breathing. DUPIXENT may also help reduce the amount of oral
corticosteroids you need while preventing severe asthma attacks and
improving your breathing. DUPIXENT is not used to treat sudden
breathing problems. It is not known if DUPIXENT is safe and
effective in children with asthma under 6 years of age.
- with other medicines for the maintenance treatment of chronic
rhinosinusitis with nasal polyposis (CRSwNP) in adults whose
disease is not controlled. It is not known if DUPIXENT is safe and
effective in children with chronic rhinosinusitis with nasal
polyposis under 18 years of age.
- to treat adults and children 12 years of age and older, who
weigh at least 88 pounds (40 kg), with eosinophilic esophagitis
(EoE). It is not known if DUPIXENT is safe and effective in
children with eosinophilic esophagitis under 12 years of age and
who weigh at least 88 pounds (40 kg).
- to treat adults with prurigo nodularis (PN). It is not known if
DUPIXENT is safe and effective in children with prurigo nodularis
under 18 years of age.
IMPORTANT SAFETY INFORMATION
Do not use if you are allergic to dupilumab or to any of
the ingredients in DUPIXENT®.
Before using DUPIXENT, tell your healthcare
provider about all your medical conditions, including if
you:
- have eye problems.
- have a parasitic (helminth) infection.
- are scheduled to receive any vaccinations. You should not
receive a "live vaccine" right before and during treatment with
DUPIXENT.
- are pregnant or plan to become pregnant. It is not known
whether DUPIXENT will harm your unborn baby.
-
- A pregnancy registry for women who take DUPIXENT during
pregnancy collects information about the health of you and your
baby. To enroll or get more information call 1-877-311-8972 or go
to https://mothertobaby.org/ongoing-study/dupixent/.
- are breastfeeding or plan to breastfeed. It is not known
whether DUPIXENT passes into your breast milk.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the- counter medicines, vitamins,
and herbal supplements.
Especially tell your healthcare provider if you are
taking oral, topical, or inhaled corticosteroid medicines; have
asthma and use an asthma medicine; or have atopic dermatitis,
chronic rhinosinusitis with nasal polyposis, eosinophilic
esophagitis, or prurigo nodularis and also have asthma. Do
not change or stop your corticosteroid medicine or other asthma
medicine without talking to your healthcare provider. This may
cause other symptoms that were controlled by the corticosteroid
medicine or other asthma medicine to come back.
DUPIXENT can cause serious side effects, including:
- Allergic reactions.
DUPIXENT can cause allergic reactions that can sometimes be
severe. Stop using DUPIXENT and tell your healthcare provider
or get emergency help right away if you get any of the following
signs or symptoms: breathing problems or wheezing, swelling of the
face, lips, mouth, tongue or throat, fainting, dizziness, feeling
lightheaded, fast pulse, fever, hives, joint pain, general ill
feeling, itching, skin rash, swollen lymph nodes, nausea or
vomiting, or cramps in your stomach-area.
- Eye problems. Tell your healthcare provider if you have
any new or worsening eye problems, including eye pain or changes in
vision, such as blurred vision. Your healthcare provider may send
you to an ophthalmologist for an exam if needed.
- Inflammation of your blood vessels.
Rarely, this can happen in people with asthma who receive DUPIXENT.
This may happen in people who also take a steroid medicine by mouth
that is being stopped or the dose is being lowered. It is not known
whether this is caused by DUPIXENT. Tell your healthcare provider
right away if you have: rash, chest pain, worsening shortness of
breath, a feeling of pins and needles or numbness of your arms or
legs, or persistent fever.
- Joint aches and pain. Some people who use DUPIXENT have
had trouble walking or moving due to their joint symptoms, and in
some cases needed to be hospitalized. Tell your healthcare provider
about any new or worsening joint symptoms. Your healthcare provider
may stop DUPIXENT if you develop joint symptoms.
The most common side effects include:
- Eczema: injection site reactions, eye and eyelid
inflammation, including redness, swelling, and itching, sometimes
with blurred vision, cold sores in your mouth or on your lips, and
high count of a certain white blood cell (eosinophilia).
- Asthma: injection site reactions, high count of a
certain white blood cell (eosinophilia), pain in the throat
(oropharyngeal pain), and parasitic (helminth) infections.
- Chronic Rhinosinusitis
with Nasal Polyposis: injection site reactions, eye and eyelid
inflammation, including redness, swelling, and itching, sometimes
with blurred vision, high count of a certain white blood cell
(eosinophilia), gastritis, joint pain (arthralgia), trouble
sleeping (insomnia), and toothache.
- Eosinophilic Esophagitis: injection site reactions,
upper respiratory tract infections, cold sores in your mouth or on
your lips, and joint pain (arthralgia).
- Prurigo Nodularis: eye and eyelid inflammation,
including redness, swelling, and itching, sometimes with blurred
vision, herpes virus infections, common cold symptoms
(nasopharyngitis), dizziness, muscle pain, and diarrhea.
Tell your healthcare provider if you have any side effect that
bothers you or that does not go away. These are not all the
possible side effects of DUPIXENT. Call your doctor for medical
advice about side effects. You are encouraged to report negative
side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.
Use DUPIXENT exactly as prescribed by your healthcare provider.
It's an injection given under the skin (subcutaneous injection).
Your healthcare provider will decide if you or your caregiver can
inject DUPIXENT. Do not try to prepare and inject DUPIXENT
until you or your caregiver have been trained by your healthcare
provider. In children 12 years of age and older, it's recommended
DUPIXENT be administered by or under supervision of an adult. In
children 6 months to less than 12 years of age, DUPIXENT should be
given by a caregiver.
Please see accompanying full
Prescribing
Information
including Patient
Information.
About Regeneron
Regeneron is a leading biotechnology
company that invents, develops and commercializes life-transforming
medicines for people with serious diseases. Founded and led for
nearly 35 years by physician-scientists, our unique ability to
repeatedly and consistently translate science into medicine has led
to nine FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, such as
VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully human antibodies and
bispecific antibodies, and through ambitious research initiatives
such as the Regeneron Genetics Center®, which is
conducting one of the largest genetics sequencing efforts in the
world.
For more information, please visit www.Regeneron.com or follow
@Regeneron on Twitter.
About Sanofi
We are an innovative global healthcare
company, driven by one purpose: we chase the miracles of science to
improve people's lives. Our team, across some 100 countries, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Regeneron Forward-Looking Statements and Use of Digital
Media
This press release includes forward-looking statements that
involve risks and uncertainties relating to future events and the
future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron"
or the "Company"), and actual events or results may differ
materially from these forward-looking statements. Words such as
"anticipate," "expect," "intend," "plan," "believe," "seek,"
"estimate," variations of such words, and similar expressions are
intended to identify such forward-looking statements, although not
all forward-looking statements contain these identifying words.
These statements concern, and these risks and uncertainties
include, among others, the impact of SARS-CoV-2 (the virus that has
caused the COVID-19 pandemic) on Regeneron's business and its
employees, collaborators, and suppliers and other third parties on
which Regeneron relies, Regeneron's and its collaborators' ability
to continue to conduct research and clinical programs, Regeneron's
ability to manage its supply chain, net product sales of products
marketed or otherwise commercialized by Regeneron and/or its
collaborators or licensees (collectively, "Regeneron's Products"),
and the global economy; the nature, timing, and possible success
and therapeutic applications of Regeneron's Products and product
candidates being developed by Regeneron and/or its collaborators or
licensees (collectively, "Regeneron's Product Candidates") and
research and clinical programs now underway or planned, including
without limitation Dupixent® (dupilumab) for the
treatment of adults with moderate-to-severe prurigo nodularis who
are candidates for systemic therapy; uncertainty of the
utilization, market acceptance, and commercial success of
Regeneron's Products and Regeneron's Product Candidates and the
impact of studies (whether conducted by Regeneron or others and
whether mandated or voluntary), including the studies discussed or
referenced in this press release, on any of the foregoing or any
potential regulatory approval of Regeneron's Products and
Regeneron's Product Candidates; the likelihood, timing, and scope
of possible regulatory approval and commercial launch of
Regeneron's Product Candidates and new indications for Regeneron's
Products, such as Dupixent for the treatment of pediatric
eosinophilic esophagitis, hand and foot atopic dermatitis, chronic
inducible urticaria-cold, chronic spontaneous urticaria, chronic
pruritis of unknown origin, chronic obstructive pulmonary disease
with evidence of type 2 inflammation, chronic rhinosinusitis
without nasal polyposis, allergic fungal rhinosinusitis, allergic
bronchopulmonary aspergillosis, bullous pemphigoidand, and other
potential indications; the ability of Regeneron's collaborators,
licensees, suppliers, or other third parties (as applicable) to
perform manufacturing, filling, finishing, packaging, labeling,
distribution, and other steps related to Regeneron's Products and
Regeneron's Product Candidates; the ability of Regeneron to manage
supply chains for multiple products and product candidates; safety
issues resulting from the administration of Regeneron's Products
(such as Dupixent) and Regeneron's Product Candidates in patients,
including serious complications or side effects in connection with
the use of Regeneron's Products and Regeneron's Product Candidates
in clinical trials; determinations by regulatory and administrative
governmental authorities which may delay or restrict Regeneron's
ability to continue to develop or commercialize Regeneron's
Products and Regeneron's Product Candidates, including without
limitation Dupixent; ongoing regulatory obligations and oversight
impacting Regeneron's Products, research and clinical programs, and
business, including those relating to patient privacy; the
availability and extent of reimbursement of Regeneron's Products
from third-party payers, including private payer healthcare and
insurance programs, health maintenance organizations, pharmacy
benefit management companies, and government programs such as
Medicare and Medicaid; coverage and reimbursement determinations by
such payers and new policies and procedures adopted by such payers;
competing drugs and product candidates that may be superior to, or
more cost effective than, Regeneron's Products and Regeneron's
Product Candidates; the extent to which the results from the
research and development programs conducted by Regeneron and/or its
collaborators or licensees may be replicated in other studies
and/or lead to advancement of product candidates to clinical
trials, therapeutic applications, or regulatory approval;
unanticipated expenses; the costs of developing, producing, and
selling products; the ability of Regeneron to meet any of its
financial projections or guidance and changes to the assumptions
underlying those projections or guidance; the potential for any
license, collaboration, or supply agreement, including Regeneron's
agreements with Sanofi and Bayer (or their respective affiliated
companies, as applicable) to be cancelled or terminated; and risks
associated with intellectual property of other parties and pending
or future litigation relating thereto (including without limitation
the patent litigation and other related proceedings relating to
EYLEA® (aflibercept) Injection,
Praluent® (alirocumab), and
REGEN-COV® (casirivimab and imdevimab)), other
litigation and other proceedings and government investigations
relating to the Company and/or its operations, the ultimate outcome
of any such proceedings and investigations, and the impact any of
the foregoing may have on Regeneron's business, prospects,
operating results, and financial condition. A more complete
description of these and other material risks can be found in
Regeneron's filings with the U.S. Securities and Exchange
Commission, including its Form 10-K for the year ended December 31, 2021 and its Form 10-Q for the
quarterly period ended September 30,
2022. Any forward-looking statements are made based on
management's current beliefs and judgment, and the reader is
cautioned not to rely on any forward-looking statements made by
Regeneron. Regeneron does not undertake any obligation to update
(publicly or otherwise) any forward-looking statement, including
without limitation any financial projection or guidance, whether as
a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website
(http://newsroom.regeneron.com) and its Twitter feed
(http://twitter.com/regeneron).
Sanofi Disclaimers or Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that COVID-19 will have on us, our customers, suppliers,
vendors, and other business partners, and the financial condition
of any one of them, as well as on our employees and on the global
economy as a whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31, 2021. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Regeneron
Contacts:
Media
Relations
Hannah
Kwagh
Tel: +1
914-847-6314
Hannah.Kwagh@regeneron.com
|
Investor
Relations
Vesna
Tosic
Tel: +1
914-847-5443
Vesna.Tosic@regeneron.com
|
Sanofi
Contacts:
Media
Relations
Sally
Bain
Tel: +1
617-834-6026
Sally.Bain@sanofi.com
|
Investor
Relations
Eva
Schaefer-Jansen
Tel: +33 7 86 80 56
39
eva.schaefer-jansen@sanofi.com
Arnaud
Delepine
Tel: +33 (0)6 73 69 36
93
arnaud.delepine@sanofi.com
Corentine
Driancourt
Tel: +33 (0)6 40 56
92
corentine.driancourt@sanofi.com
Felix
Lauscher
Tel: +1
908-612-7239
felix.lauscher@sanofi.com
Priya
Nanduri
Tel: +1
617-764-6418
priya.nanduri@sanofi.com
Nathalie
Pham
Tel: +33 (0)7 85 93 30
17
nathalie.pham@sanofi.com
|
View original
content:https://www.prnewswire.com/news-releases/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis-301703698.html
SOURCE Regeneron Pharmaceuticals, Inc.